AEHR TEST SYSTEMS WKN: 908802 ISIN: US00760J1088 Kürzel: AYB Forum: Aktien Thema: Hauptdiskussion
10,78 USD
-4,01 %-0,45
16. Nov, 02:00:00 Uhr,
Nasdaq
Kommentare 1.939
Käseraspel,
16.07.2024 22:49 Uhr
0
Ich bin für heute zufrieden 😂 Darf morgen aber gerne weitergehen ;)
Aktenhai,
16.07.2024 22:51 Uhr
0
neuer Angriff auf die 20$ ....da kommt noch was ....Spannung pur 🍻 🍻 🍻
Aktenhai,
16.07.2024 22:43 Uhr
0
Aehr Test Systems Reports Fiscal 2024 Fourth Quarter and Full Year Financial Results and Provides Fiscal 2025 Full Year Financial Guidance
07/16/2024
FREMONT, CA / ACCESSWIRE / July 16, 2024 / Aehr Test Systems (NASDAQ:AEHR), a worldwide supplier of semiconductor test and burn-in equipment, today announced financial results for its fiscal 2024 fourth quarter and full year ended May 31, 2024.
Fiscal Fourth Quarter Financial Results:
Net revenue was $16.6 million, compared to $22.3 million in the fourth quarter of fiscal 2023
GAAP net income was $23.9 million, or $0.81 per diluted share, which includes the impact of a tax benefit resulting from the release of the Company's full income tax valuation allowance of approximately $20.8 million, compared to GAAP net income of $6.1 million, or $0.21 per diluted share, in the fourth quarter of fiscal 2023.
Non-GAAP net income was $24.7 million, or $0.84 per diluted share, which includes the tax benefit and excludes acquisition related costs and the impact of stock-based compensation, compared to non-GAAP net income of $6.8 million, or $0.23 per diluted share, in the fourth quarter of fiscal 2023.
Bookings were $4.0 million for the quarter
Backlog as of May 31, 2024, was $7.3 million. Effective backlog, which includes all orders received since the end of the fourth quarter, is $20.8 million.
Total cash and cash equivalents as of May 31, 2024 were $49.2 million, up from $47.6 million at February 29, 2024
Fiscal Year Financial Results:
Net revenue was a record $66.2 million, compared to $65.0 million in fiscal 2023
GAAP net income was $33.2 million, or $1.12 per diluted share, which includes the impact of a tax benefit resulting from the release of the Company's full income tax valuation allowance of approximately $20.8 million recognized in the fourth quarter, compared to GAAP net income of $14.6 million, or $0.50 per diluted share, in fiscal 2023.
Non-GAAP net income, which includes the tax benefit and excludes acquisition related costs and the impact of stock-based compensation, was $35.8 million, or $1.21 per diluted share, compared to non-GAAP net income of $17.3 million, or $0.59 per diluted share, in fiscal 2023.
An explanation of the use of non-GAAP financial measures and a reconciliation of Aehr's non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying tables.
Käseraspel,
16.07.2024 22:42 Uhr
0
Hast du die Earnings? Ich finde nix, Techii sagt irgendwas von 730% overperformance?
Meistdiskutiert
|
Thema | ||
---|---|---|---|
1 | Trading- und Aktien-Chat | ||
2 | MicroStrategy | +3,76 % | |
3 | XRP zu USD Hauptdiskussion | +22,81 % | |
4 | für alle, die es ehrlich meinen beim Traden. | ||
5 | Palantir | +11,49 % | |
6 | Marathon Digital Holdings | +1,44 % | |
7 | IOVANCE BIOTHERAP.DL-,001 Hauptdiskussion | -4,71 % | |
8 | Forum | ±0,00 % | |
9 | Phunware | -9,44 % | |
10 | BAYER Hauptdiskussion | -0,56 % | Alle Diskussionen |
Aktien
|
Thema | ||
---|---|---|---|
1 | MicroStrategy | +3,76 % | |
2 | Marathon Digital Holdings | +1,44 % | |
3 | Palantir | +11,49 % | |
4 | Forum | ±0,00 % | |
5 | IOVANCE BIOTHERAP.DL-,001 Hauptdiskussion | -4,71 % | |
6 | BAYER Hauptdiskussion | -0,56 % | |
7 | Phunware | -9,44 % | |
8 | BED BATH & BEYOND Hauptdiskussion | ±0,00 % | |
9 | DPCM Capital Hauptdiskussion | -12,57 % | |
10 | Canada Nickel Company Hauptdiskussion | -3,26 % | Alle Diskussionen |